The Synosia business strategy involves not only acquiring clinically enabled compounds but also strategic partnerships.
In January 2007, Synosia Therapeutics announced a broad partnership with Roche to develop five drug candidates in multiple psychiatric and neurological indications.
In April 2007, we announced an exclusive licensing agreement with Novartis for an advanced product candidate for the treatment of anxiety and bipolar mood disorders.
In May 2007, we announced our third agreement with a pharmaceutical partner through a license from Syngenta to develop a potentially novel treatment for Parkinson's disease.
